Form 4: Dyne Therapeutics Director Granted 35,000 Stock Options

Dyne Therapeutics, Inc. Director Catherine Stehman-Breen was granted 35,000 stock options with an exercise price of $11.96, vesting by May 2026.

Summary

• Catherine Stehman-Breen, a Director of Dyne Therapeutics, Inc. (DYN), was granted 35,000 stock options.
• The options have an exercise price of $11.96 per share.
• The grant date for these options was May 30, 2025.
• The shares underlying the option are scheduled to vest in full on the earlier of May 30, 2026, or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service.
• The options have an expiration date of May 29, 2035.
• The filing also includes a Limited Power of Attorney for Section 16 reporting obligations, signed by Catherine Stehman-Breen on June 3, 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the grant of stock options to a director is a standard practice that aligns interests and incentivizes performance, without indicating any negative operational or financial news.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• The exercise price of $11.96 provides a clear benchmark for future stock performance relative to the grant.

Future Outlook

The granted stock options are scheduled to vest in full on the earlier of May 30, 2026, or the date of the Issuer's 2026 Annual Meeting of Stockholders, contingent on the director's continued service.

Industry Context

This is a routine insider transaction filing (Form 4) for a director's equity compensation, common in the biotechnology and pharmaceutical industries to attract and retain talent and align interests with shareholders. It does not provide broader industry trends or competitive analysis.

Corporate Governance

Related Party Transactions

• The grant of 35,000 stock options to Catherine Stehman-Breen, a Director of Dyne Therapeutics, Inc., constitutes a transaction between the company and a related party (a director).

Stakeholder Impact

• Shareholders: The option grant aligns the director's financial interests with shareholder value creation, as the options gain value if the stock price increases.
• Employees: While not directly impacting all employees, such grants are part of a broader compensation strategy that can influence company culture and retention of key personnel.

Next Steps

• The granted stock options will vest on the earlier of May 30, 2026, or the date of Dyne Therapeutics' 2026 Annual Meeting of Stockholders, subject to Catherine Stehman-Breen's continued service.

Key Dates

Recommendation

Keywords

Dyne Therapeutics, DYN, Stock Options, SEC Form 4, Insider Transaction, Director Compensation, Equity Grant, Biotechnology, Pharmaceuticals